Susan Schnitker, APRN
Family · Seymour, INNPI 1508236209
Payments from drug & device makers
Across 197 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$746
- Novo Nordisk$642
- GSK$474
- Lilly USA, LLC$435
- Novartis$361
- Merck$207
- plus $558 from 17 others
What the payments were for
- Food & beverage$3,423100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $746 |
| Novo Nordisk | 47 | $642 |
| GSK | 32 | $474 |
| Lilly USA, LLC | 32 | $435 |
| Novartis | 16 | $361 |
| Merck | 13 | $207 |
| AbbVie | 7 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Boehringer Ingelheim | 2 | $42 |
| Exact Sciences | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Abbott | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Pfizer | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Genentech USA, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$353
- FARXIGA$353
- AIRSUPRA$353
How this compares
$3,423 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $48,864 |
| OzempicSemaglutide | 34 | $42,347 |
| MounjaroTirzepatide | 31 | $32,795 |
| JardianceEmpagliflozin | 27 | $29,206 |
| FarxigaDapagliflozin Propanediol | 18 | $21,495 |
| EliquisApixaban | 27 | $19,469 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $2,381 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,826 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,429 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $1,153 |
| Potassium Chloride | 30 | $1,134 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 12 | $959 |
| Atorvastatin Calcium | 118 | $760 |
| Pantoprazole Sodium | 63 | $759 |
| Cefdinir | 43 | $722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $474 | $48,86460 claims |
| Novo NordiskOzempic | $642 | $42,34734 claims |
| Lilly USA, LLCMounjaro | $435 | $32,79531 claims |
| Boehringer IngelheimJardiance | $42 | $29,20627 claims |
| AstraZenecaFarxiga | $746 | $21,49518 claims |
| PfizerEliquis, Paxlovid | $13 | $20,89838 claims |
| AbbVieSynthroid | $141 | $71518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Seymour
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.